CLDF Title
Home | Contact Us | Bookmark
NASH HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
Embassy of Education  
Slide Library Webcasts Abstract Library LiverQ Academy
 
Back  
 
UK cost agency not ready to back Gilead hepatitis C drug

UK cost agency not ready to back Gilead hepatitis C drug

By Reuters Staff

LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE said on Monday it needed more information about Gilead Sciences' pricey new hepatitis C drug Sovaldi before deciding if it should be used on the state health service.

The National Institute for Health and Care Excellence (NICE) said it was "minded not to recommend" the drug, which is also known as sofosbuvir. The decision poses a hurdle to its widespread adoption in Britain.

"The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients," said Carole Longson, director of the NICE Centre for Health Technology Evaluation.

"However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer."

Sovaldi is far more effective and better-tolerated than older treatments, but its high cost has provoked criticism from healthcare campaigners and insurers.

The U.S. price for a 12-week course of treatment with Sovaldi is $84,000, or $1,000 for each once-daily pill. The price in Britain has been set lower at around 35,000 pounds ($58,800).

 
 
 
 

Subscribe

Be the first to know about our latest upcoming programs and events!

CLDF

Follow us

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2022 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.